Allianz Asset Management GmbH - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$235,764
+0.6%
33,3000.0%0.00%
Q2 2023$234,432
+25.5%
33,300
+48.7%
0.00%
Q1 2023$186,816
-64.9%
22,400
-51.6%
0.00%
-100.0%
Q4 2022$531,524
-29.3%
46,300
-22.4%
0.00%
-50.0%
Q3 2022$752,000
-84.1%
59,700
-86.6%
0.00%
-50.0%
Q2 2022$4,715,000
-5.0%
445,675
+46.0%
0.00%0.0%
Q1 2022$4,962,000
+36.2%
305,179
+16.0%
0.00%
+33.3%
Q4 2021$3,642,000
+76.4%
263,115
+83.1%
0.00%
+50.0%
Q3 2021$2,065,000
+3076.9%
143,708
+953.8%
0.00%
Q2 2020$65,000
-79.0%
13,637
-87.4%
0.00%
Q3 2019$309,000
-69.3%
107,890
-59.3%
0.00%
-100.0%
Q2 2019$1,005,000
-63.1%
265,144
-20.8%
0.00%
-66.7%
Q1 2019$2,725,000
+25.3%
334,728
+24.2%
0.00%
+50.0%
Q4 2018$2,174,000
+2.4%
269,403
-3.2%
0.00%0.0%
Q3 2018$2,124,000
+60.9%
278,418
+20.8%
0.00%
+100.0%
Q2 2018$1,320,000
+19.5%
230,413
-0.6%
0.00%0.0%
Q1 2018$1,105,000
+36.4%
231,761
+40.5%
0.00%0.0%
Q4 2017$810,000
-3.0%
164,978
+3.5%
0.00%0.0%
Q3 2017$835,000
+27.7%
159,364
+35.5%
0.00%0.0%
Q2 2017$654,000
-35.1%
117,637
-2.0%
0.00%0.0%
Q1 2017$1,008,000
+308.1%
119,978
+453.7%
0.00%
Q3 2015$247,00021,6700.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders